Radium-223 for Prostate Cancer

This trial aims to explore a new imaging technique called LC-QSPECT to assess its effectiveness in tracking the distribution of Radium-223, a treatment for prostate cancer that has spread to bones. The goal is to better understand how this treatment spreads throughout the body, which can help personalize doses and improve overall treatment. This trial may be suitable for individuals with prostate cancer that does not respond to hormone therapy and has spread to the bones. Participants will undergo imaging and provide samples to assist researchers in gathering data. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research that could lead to more personalized and effective treatments for prostate cancer.

The trial information does not specify whether you need to stop taking your current medications. However, you cannot participate if you are using other radiopharmaceuticals at the same time.

Research has shown that Radium-223, also known as Xofigo, is generally safe for patients with prostate cancer that has spread to the bones. It has been used safely in many patients, with some followed for up to 95 months, and most did not experience serious side effects. One study found it effective and well-tolerated by Taiwanese patients with similar conditions.

Most treatments for prostate cancer, such as hormone therapy or chemotherapy, aim to slow cancer growth or alleviate symptoms. But Radium-223 works differently, targeting cancerous bone metastases directly with radiation. This treatment is unique because it mimics calcium and integrates into the bone, delivering targeted radiation to kill cancer cells while sparing surrounding healthy tissue. Researchers are excited about Radium-223 because it offers a more precise approach, potentially reducing side effects and improving quality of life for patients with advanced prostate cancer.

Research has shown that Radium-223 effectively treats prostate cancer that has spread to the bones. One study found that patients treated with Radium-223 lived for an average of 15.7 months, longer than with some other treatments. Another study demonstrated that Radium-223 not only extended patients' lives but also reduced their pain. It works by delivering radiation directly to the bones, targeting cancer cells while leaving healthy tissue mostly unharmed. This targeted approach makes it a valuable option for men with advanced prostate cancer that has spread to the bones. Participants in this trial will receive Radium-223 as part of the standard of care, with additional monitoring through noninvasive LC-QSPECT scans and other assessments.²³⁴⁶⁷